Cardiovascular Systems Inc. (Nasdaq:CSII) recently announced that it has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC). The shelf registration statement will permit the company to sell up to $75 million of equity or debt securities, providing greater flexibility to take advantage of financing opportunities as needed. As of the date of this release, CSI has no specific plans to offer, and is not required to offer, the securities covered by the registration statement.

Cardiovascular Systems, Inc., a medical device company, focuses on developing and commercializing interventional treatment systems for vascular disease.

*******

Crown Equity Holdings, Inc. (CRWE)

There are several internet advertising advantages and opportunities, as the Internet is so commonly accessible, and businesses may reach millions of prospective consumers with few clicks on their computers.

Online marketers with the help of Internet advertising agency may afford a pay-per-click (PPC) program with a top web site. Here, they may compare or evaluate prices for viewing personal interests, which is one of the most lucrative Internet advertising advantages of all.

One of the most admired Internet advertising advantages is that it helps online marketers to reach their target customer base. Internet advertising provides tools such as e-mail marketing by which online marketers may reach thousands of people in minutes.

Crown Equity Holdings advertises your business adjacent with their digital network content to their targeted audience, which are educated high income individuals.

Crown Equity Holdings, Inc., together with its digital network, currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers. Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

Crown Equity Holdings, Inc. announced that it has extended its CRWENEWSWIRE global platform web presence and is now publishing online news and information to the following countries: Argentina, Australia, Brazil, China, France, Germany, India, Ireland, Italy, Japan, Malaysia, Mexico, New Zealand, Russia, Singapore, South Africa, South Korea, Spain, Taiwan, United Arab Emirates and the United Kingdom, using their specific country code domain and native language.

For more information, visit http://www.crownequityholdings.com

*******

Verigy, Ltd. (Nasdaq:VRGY) recently reported financial results for its second quarter ended April 30, 2011. Revenue for the second quarter was $112 million, a decrease of $8 million, or 7 percent, from the $120 million reported in both the prior quarter and the comparable quarter a year ago. Orders grew approximately 30 percent sequentially to $127 million in the second quarter, resulting in a book-to-bill ratio of 1.13. GAAP net loss for the second quarter was $40 million or ($0.66) per share, compared to a net loss of $5 million, or ($0.08) per share in the first quarter, and a net loss of $1 million or ($0.02) per share in the same period a year ago.

Verigy Ltd., together with its subsidiaries, designs, develops, manufactures, and sells test systems and solutions for the semiconductor industry primarily in North America, Europe, and Asia.

*******

Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) recently announced the commercial launch of DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in patients 18 years of age and older. In two large Phase 3 clinical studies, DIFICID had clinical response rates at the end of the 10-day treatment period that were non-inferior to oral vancomycin. In addition, DIFICID was superior to vancomycin in sustained clinical response, defined as clinical response at the end of treatment and survival without proven or suspected CDAD recurrence through 25 days beyond the end of treatment. With the commercial availability of DIFICID, Optimer is initiating a Patient Assistance Program to help eligible uninsured and underinsured patients gain access to this important treatment option. DIFICID is the only FDA-approved treatment for CDAD that has demonstrated superiority to vancomycin in sustained clinical response and the first new drug approved for the treatment of CDAD in more than 25 years.

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products worldwide.

***************************************
Sign up for free stock alerts at http://www.pennygovernance.com/signup

***************************************
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(read more @ http://pennygovernance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.